ABSTRACT: Bronchial hyperresponsiveness (BHR), an abnormal increase in airflow limitation following the exposure to a stimulus, is an important pathophysiological characteristic of bronchial asthma. Because of heterogeneity of the airway response to different stimuli, the latter have been divided into direct and indirect stimuli. Direct stimuli cause airflow limitation by a direct action on the effector cells involved in the airflow limitation, while indirect stimuli exert their action essentially on inflammatory and neuronal cells that act as an intermediary between the stimulus and the effector cells.
Bronchial hyperresponsiveness (BHR) is an important pathophysiological characteristic of bronchial asthma that can explain many of its clinical features. Bronchial or airway hyperresponsiveness is an abnormal increase in airflow limitation following the exposure to a stimulus. The word "abnormal" refers to a comparison with the airway response to the same agonist, using the same method to measure the airflow limitation, in a group of healthy subjects. The wording "airflow limitation" is chosen because it encompasses the different mechanisms that can lead to a decrease in the parameters of airflow [1] .
In order to highlight the heterogeneity of the airway response to the different stimuli and to better understand the effect of treatment on BHR, the stimuli have been divided into direct and indirect [2±4] . Direct stimuli cause airflow limitation by a direct action on the effector cells involved in the airflow limitation, such as airway smooth muscle cells, bronchial vascular endothelial cells and mucus producing cells. Indirect stimuli cause airflow limitation by an action on cells other than the effector cells; these cells then interact in a second time with these effector cells ( fig. 1 ). Cells that act as an intermediary between the indirect stimuli and the effector cells are inflammatory cells (such as mast cells) and neuronal cells. The stimuli themselves have been classified according to the dominant mechanism of airflow limitation in response to the stimulus (table 1); some stimuli have both a direct and an indirect activity ( fig. 2 ).
Direct stimulus
Indirect stimulus The aim of the present manuscript is to review the clinical and experimental studies, dissecting the mechanisms involved in indirect BHR; the discussion centres around data obtained in patients with asthma. When such data are not currently available, results obtained from animal models or from experiments on isolated human bronchi are included. There are important variations in the methodology of the different provocations; fortunately, there is an increasing awareness concerning the importance of this issue, and attempts towards greater standardization between different centres have resulted in the publication of guidelines [4, 5] . Increasingly these indirect challenges are considered to provide additional information in the diagnosis and monitoring of asthma in children and adults. They are increasingly used in studies to assess the antiasthmatic effect of an intervention. Currently an European Respiratory Society (ERS) Task Force on "Indirect challenges" is working on a summary report with recommendations.
Pharmacological stimuli
Adenosine 5'-monophosphate Adenosine (9-b-D-ribofuranosyl-6-aminopurine) is a naturally occurring nucleoside that serves an autocoid function in a large number of physiological systems, and may be considered as a secondary product of the inflammatory response. Most adenosine is derived from cleavage of the nucleotide adenosine 5'-monophosphate (AMP). AMP released from cells undergoes hydrolysis by the ubiquitous ectoenzyme 5'-nucleotidase (EC 3.1.3.5), which is principally associated with the cell plasma membrane, to produce adenosine that may be either salvaged to produce new AMP after re-uptake in the cell or degraded to its end product uric acid, which is excreted via the urine [6] .
Adenosine exerts its effects on human cells through interaction with specific adenosine (P1) receptors, of which four subtypes (A 1 , A 2A , A 2B , and A 3 ) have been described [7] . Our knowledge on the adenosine receptors mediating adenosine-induced airflow limitation is rather limited at present. The A 1 , A 2B , and A 3 receptors have been shown to be involved in various animal and human models, but the development of specific and potent adenosine receptor agonists and antagonists for use in vivo in asthma must be awaited to further elucidate the relative importance of these receptors [8] . In particular, the potential role of A 2B receptors is being increasingly recognized [9] .
Inhalation of adenosine was shown to have no detectable effect on airway calibre in normal subjects, but elicited a concentration-dependent airflow limitation in patients with both allergic and nonallergic asthma [10] , and in atopic, nonasthmatic subjects [11] . Responsiveness to adenosine is greater in atopic asthmatics than in atopic normal subjects, without a sharp cut-off between the groups [12] . Repeated inhalation of AMP by atopic nonasthmatics induces airway refractoriness through mechanisms likely to involve depletion of mast cell mediators or downregulation of purinoreceptors. The refractory period lasts~4 h [13] . The airway responsiveness to AMP increases after inhalation of hypertonic saline [14] . Adenosine 5'-monophosphate (maximal concentration: 1.08 M) is much more hydrosoluble than adenosine itself (maximal concentration: 25 mM) and is therefore preferred for inhalation challenges [12] .
In vitro studies clearly indicated that mast cell derived mediators are involved in the adenosine response. Adenosine potentiates histamine release from human lung mast cells after anti-immunoglobulin (Ig)E challenge through A 2 receptor stimulation [15] ; similarly, adenosine potentiates the release of both preformed (histamine) and newly formed leukotriene C (LTC4) mediators from immunologically activated human lung mast cells, most probably via an A 2 -mediated mechanism [16] . In addition, mast cell derived mediators (prostaglandin D 2 (PGD 2 ), histamine, and tryptase) were found to be markedly increased in bronchoalveolar lavage fluid, obtained immediately after endobronchial AMP instillation in asthmatics [17] . Finally, plasma histamine increased significantly following AMP challenge in atopic nonasthmatics [11] , while serum neutrophil chemotactic factor showed a significant elevation in asthmatics, but not in normal subjects following adenosine bronchoprovocation [18] .
In vitro studies on isolated human airways confirmed that bronchi from asthmatics are more sensitive to adenosine than are bronchi from nonasthmatics. The contractile effect of adenosine was inhibited by nonselective A 1 and dual A 1 /A 2 receptor antagonists. In addition, the contractile response to adenosine was reduced by either antihistamines or drugs that inhibited the action or formation of leukotrienes. Moreover, when these two classes of drugs were combined, the response to adenosine was abolished [19] . These findings are in agreement with the observation in clinical studies that oral pretreatment with 180 mg of the H1 receptor antagonist terfenadine had a major inhibitory effect on the airway response to AMP in atopic [20] and nonatopic asthma [21] (table 2) . The confirmation of a leukotriene component in the AMP-induced airflow limitation in asthma was obtained in a subsequent clinical study, where it was shown that oral pretreatment with 200 mg of ABT-761 (atreleuton), a 5-lipoxygenase inhibitor, reduced the area under the FEV1-time curve by >80% [22] . The results from studies with cyclo-oxygenase inhibitors show that the newly formed prostanoids also play an, albeit modest, role in the AMP-induced airflow limitation [23±26] .
Enhancement of mast cell mediator release, although prominent, is not the only mechanism accounting for the airflow limitation by inhaled adenosine. Pretreating asthmatics with 500 mg of the nebulized anticholinergic ipratropium bromide resulted in a protective 2.5-fold shift of provocative concentration of the drug causing a 20% fall in forced expiratory volume in one second (PC20) [27] . Similarly, inhalation of 40 mg of ipratropium bromide via pMDI in asthmatics afforded a 2.2-fold protective shift of provocative dose of the drug causing a 20% fall in forced expiratory volume in one second (PD20) AMP [28] . These findings suggest that cholinergic, vagal pathways contribute a small, but significant component of the airflow limitation induced by inhaled AMP in asthma. Pretreatment with the inhaled neutral endopeptidase (NEP) inhibitor phosphoramidon did not have an effect on AMP-induced BHR; this suggests that stimulation of airway nerves with local release of tachykinins does not play an important role in the airway response to adenosine [29] .
Inhaled SCG and nedocromil sodium (NED) are highly effective in attenuating the airway response to adenosine and AMP challenge in atopic nonasthmatics [30] , atopic asthmatics [31, 32] , and nonatopic asthmatics [32] . The exact mechanism of action of these molecules is not fully understood; it is suggested that their actions, such as the prevention of release of mediators from mast cells or eosinophils, or the inhibition of firing of sensory nerve fibres, are the result of their blocking activity on chloride channels [33] .
It is not clear whether inhalation of adenosine activates the nitric oxide (NO) synthase pathway. In a trial on the effect of inhaled N-nitro-L-arginine methyl ester (L-NA-ME), a NO synthase inhibitor, a small (approximately one doubling dose) increase in airway responsiveness to both histamine and adenosine was noted [34] .
Inhalation of furosemide protects asthmatic airways against AMP-induced airflow limitation [35, 36] . The exact mechanism through which furosemide conveys its protective effects is not known; more than one mechanism may be involved. The fact that furosemide is more potent in protecting against indirect (e.g. AMP) when compared to direct (e.g. methacholine) bronchoconstrictor stimuli [35] , however, suggests an additional inhibitory effect on mediator release from mast cells and/or inhibition of neural pathways. Furthermore, inhaled heparin resulted in a 2.4-fold protection against AMP in atopic asthmatics; it is believed that the bronchoprotective action of heparin is also related to an inhibitory modulation of mast cell activation [37] ; this finding, however, was not confirmed in another study with a different interval between heparin inhalation and AMP challenge [38] .
Finally, the effect of inhaled glucocorticosteroids (iG-CS) on AMP challenge has been tested. Treatment with inhaled budesonide (800 mg b.d.) for 14 days was found to have a significantly greater effect on airway responsiveness to AMP when compared to the effects seen on the airway responsiveness to methacholine and sodium metabisulphite in atopic asthmatics. The rightward shifts in the dose-response curves were 2.9, 1.2 and 1.1 doubling dilutions, respectively [39] . One and two months treatment with inhaled beclomethasone diproprionate (400 mg . day -1 ) significantly increased the PD20 for AMP, but not for bradykinin or methacholine, in children with recurrent wheeze, suggesting that AMP responsiveness may be a superior marker to predict response to inhaled steroid treatment [40] . The most likely explanation for this action of iGCS is a reduction of airway mast cell numbers and/or function [40] .
In summary, although there are no selective adenosine receptor antagonists available for use in humans to date, alternative pharmacological approaches have suggested that adenosine acts indirectly through activation of specific receptors on intermediary inflammatory cells such as mast cells and possibly on afferent nerve endings. Adenosine is not merely one of a series of scientifically interesting pharmacological stimuli that cause airflow limitation in asthma, but may also be a mediator involved in asthma. AMPinduced airflow limitation may well depend on the state of airway mast cell priming and a bronchoprovocation with , and oral terfenadine (180 mg . day -1 for three days) had no effect on NKA-induced airflow limitation [64] . This is in keeping with the finding that SP (1-10 mM) does not release histamine from human lung mast cells from nonasthmatics, obtained from lung tissue [65] . Other authors, however, demonstrated that higher concentrations of SP (50 mM) were able to induce histamine release from human lung mast cells from nonasthmatics, obtained at bronchoalveolar lavage (BAL) [66] . Pretreatment with inhaled lysine-acetylsalicylate (L-ASA, 90 mg . mL -1 ) elicited a small but significant protection against NKA-induced airflow limitation; L-ASA failed to show a significant change in airway responsiveness to methacholine. These results suggest that contractile prostaglandins mediate a component of the NKA response in human asthma; their contribution to the overall response, however, is likely to be small [67] .
Several authors investigated the possible role of acetylcholine release by post-ganglionic vagal nerve endings in tachykinin-induced airflow limitation. Pretreatment with 400 mg of the inhaled anticholinergic drug oxitropium bromide in mild asthmatics did not offer a significant protection against bronchoprovocation with NKA [68] .
Others were able to demonstrate a small, but statistically significant protective effect on SP-induced airflow limitation following a pretreatment with 40 mg of inhaled ipratropium bromide, suggesting a weak cholinergic activation [63] .
A single dose of 4 mg of inhaled nedocromil sodium significantly inhibited SP-[56] and NKA-induced [69] airflow limitation in mild asthmatics. Inhalation of 40 mg of nebulized furosemide partially protects against NKAinduced airflow limitation, suggesting a suppressive action on the neurotransmission [70] . A 14-day course of inhaled steroids (fluticasone propionate, 1,000 mg . day -1 ) induced a more pronounced reduction in bronchial responsiveness to NKA as compared to methacholine [71] .
In summary, TKs are released not only from sensory nerve endings, but also from various non-neural cells, and they are of potentially greater importance as mediators of asthma than previously thought. Performing bronchial challenges with TKs is mainly of pathophysiological importance, in order to elucidate the actions of the different TKs and to study the role of the airway TK receptors. They are currently employed to evaluate newly developed TK receptor antagonists. The high cost of these peptides, however, will probably limit their use to fundamental and clinical research purposes [44] .
Bradykinin
Kinins are naturally occurring vasoactive peptides formed de novo in body fluids and tissues during inflammatory processes. Plasma kallikrein digests high molecular weight kininogen (HMWK) to generate bradykinin, while tissue kallikreins readily release kinins from both HMWK (bradykinin) and low molecular weight kininogen (LMWK) (kallidin). The decapeptide kallidin (lysyl-bradykinin) is rapidly converted to the nonapeptide bradykinin by the enzyme aminopeptidase-M. Once generated, the kinins exert their actions through interaction with specific cell surface bradykinin (B) receptors, named B 1 and B 2 . The effects of bradykinin on airways are mediated via B 2 receptors. Bradykinin is metabolized by several peptidases, the most important of which are carboxypeptidase N (kininase I), ACE (kininase II), and NEP (see tachykinins) [72] .
Inhalation of bradykinin results in a concentration-dependent airflow limitation in patients with asthma. Patients with asthma are hyperresponsive to bradykinin, when compared to normal subjects [73±77] . Similarly, local challenge of the distal airways with increasing concentrations of bradykinin, aerosolized through a wedged bronchoscope, produces a dose-dependent increase in resistance in asthmatic, but not in normal subjects [78] . Bradykinin causes maximal airflow limitation at 3±10 min, with recovery occurring within 60 min [76, 77] . In asthmatic subjects, bradykinin and kallidin, but not [desArg 9 ] bradykinin, produce a concentration-related fall in forced expiratory volume in one second (FEV1) [77] . As bradykinin and kallidin are preferential B 2 receptor agonists and [des-Arg 9 ] bradykinin is a selective B 1 receptor agonist, this suggests that the bradykinin-induced airflow limitation is B 2 receptor mediated [72] . This is in keeping with findings in isolated peripheral airways from nonasthmatic subjects: B 2 , but not B 1 receptor agonists induce contraction, and the B 2 receptor antagonist Hoe 140, but not the B 1 receptor antagonist [Leu 8 des-Arg 9 ] bradykinin, abolishes the bradykinin-induced bronchoconstriction [79, 80] .
The NEP inhibitor phosphoramidon was found to discretely increase the sensitivity to bradykinin in isolated airways from nonasthmatics [80] ; similarly, inhalation of nebulized phosphoramidon had a small, but significant enhancing effect in asthmatics [81] . The enhancing effect of phosphoramidon on bradykinin-induced airflow limitation may be the result of a direct inhibition of bradykinin metabolism and/or of the inhibition of the metabolism of endogenous tachykinins released by bradykinin.
Repeated inhalation of bradykinin induces tachyphylaxis [76, 82] that may persist for up to 3 days [83] . The phenomenon of tachyphylaxis is, however, not observed in all subjects with asthma [84] . Repeated exposure of the airways of atopic asthmatics to bradykinin and hypertonic saline results in the development of cross-refractoriness to hypertonic saline and bradykinin respectively, suggesting a shared mechanism for refractoriness produced by these stimuli [85] .
The involvement of histamine in bradykinin-induced airflow limitation appears to be very limited [86] . Extensive research has been performed on the role of cyclooxygenase (COX) products in bradykinin-induced airflow limitation. Indomethacin largely inhibited in vitro the bradykinin-induced release of the prostanoids prostaglandin (PG) PGE 2 , PGI 2 , and thromboxane (TX)A 2 from airways of nonasthmatic subjects [80] as well as the bradykinin-induced contraction of isolated nonasthmatic human airways [79, 80] , suggesting the involvement of a COX product. In addition, it was shown that cultured human tracheal smooth muscle cells from nonasthmatics release large quantities of PGE 2 in response to bradykinin stimulation. The underlying mechanisms are different for the short-term and long-term responses. Although both are mediated by B 2 receptors, short-term increases are due to the conversion by existing COX-1 of increased arachidonic acid release to PGE 2 , whereas the long-term increases are mainly due to the induction of COX-2 [87] . However, involvement of prostaglandins in bradykinin-induced airflow limitation in asthma remains controversial. Indeed, cyclooxygenase inhibitors administered orally are relatively ineffective in preventing bradykinininduced airflow limitation in asthma [76, 86] . The absence of a significant effect may be explained by the poor bioavailability of orally administered cyclooxygenase inhibitors at the level of the airways. Inhalation of L-ASA (4 mL at 90 mg . mL -1 ) was indeed more effective in attenuating bradykinin effects than the orally administered doses [88] . Similarly, the tachyphylaxis to bradykinin is not altered by oral administration of the cyclooxygenase inhibitors aspirin (1g) [76] or flurbiprofen (150 mg) [89] , suggesting that this phenomenon is not secondary to increased generation of protective prostanoids, such as PGE 2 or PGI 2 .
The thromboxane prostanoid (TP) receptor antagonist GR32191 (vapiprost) effectively antagonized bradykinininduced responses in isolated human peripheral airways, suggesting that the contractile effects of prostanoids released by bradykinin are mediated through the TP receptor [80, 90] . Furthermore, the TXA 2 synthase inhibitor dazoxiben inhibited the bradykinin-induced contraction, while the TXA 2 mimetic U-46619 induced contraction, suggesting that TXA 2 itself is involved in TP receptor stimulation [90] . Despite these results, the oral administration of 50 mg of the TP receptor antagonist BAY u 3405 failed to protect against bradykinin-induced airflow limitation in asthma, while being protective against PGD 2 -induced airflow limitation [91] . This would suggest that the airflow limitation elicited by bradykinin in asthma is not mediated through TP receptors.
The bronchoconstrictor effect of bradykinin is, at least in part, mediated via cholinergic vagal nerves, since pretreatment with ipratropium bromide significantly reduced airflow limitation in asthmatics [76] . Although bradykinin has been shown to release tachykinins in guinea-pig airways [92±94], conclusive evidence for an involvement of tachykinins in bradykinin-induced bronchoconstriction in man is lacking. The initial observation that inhalation of FK-224 (4 mg), a cyclopeptide dual tachykinin NK 1 / NK 2 receptor antagonist, attenuated inhaled bradykinininduced airflow limitation and cough in asthmatics [95] was not confirmed in a subsequent, similar trial [96] , in which inhaled FK-224 (2 mg) was only marginally protective and the magnitude of its effect similar to the spontaneous variability in bradykinin responsiveness over several weeks. Moreover, it was shown that FK-224 did not protect against inhaled NKA-induced bronchoconstriction in asthma [61] .
Cromolyn sodium and nedocromil sodium protect against bradykinin-induced bronchoconstriction in asthmatics [76, 97] . Given the apparently limited role for mast cell-derived mediators the protective effect of cromolyn sodium against bradykinin-induced airflow limitation may be the result of an action at the level of the neural reflexes [33] . Such an action has been demonstrated in the dog lung in vivo, where SCG suppressed the response of sensory "C" fibre endings to capsaicin [98] .
Pretreatment with inhaled N G -monomethyl-L-arginine (L-NMMA), a nitric oxide (NO) synthase inhibitor, significantly potentiated airflow limitation in response to inhaled bradykinin in asthmatics; this suggests that bradykinin activates the NO synthase pathway, leading to the release of NO, which in turn counteracts the bronchoconstrictor response to bradykinin. Endogenous NO therefore appears to have a bronchoprotective role in airways of asthmatic subjects [99] .
High concentrations of furosemide inhibit bradykinininduced contraction of small bronchi of nonasthmatic subjects in vitro. As it also inhibits the TX prostanoid (TP) receptor agonist U-46619-induced contraction in a competitive fashion, the mechanism of the protective effect of furosemide in bradykinin-induced bronchoconstriction in vitro may be explained at least partly by antagonism of TP receptors [100] . Inhaled furosemide (40 mg) has also been shown to provide a 5-fold protection in PC20 against inhaled bradykinin-induced airflow limitation in asthma [36] . As mentioned above, however, it could not be confirmed that TX prostanoid (TP) receptors are also mediating bradykinin-induced airflow limitation in asthmatic patients [91] .
Three weeks treatment of mild adult asthma with 1,200 mg . day -1 of inhaled budesonide attenuated to the same extent the bronchial hyperresponsiveness to bradykinin and histamine [101] . In children, treatment with 400 mg . day -1 of inhaled beclomethasone dipropionate (BDP) for three months had no significant effect on hyperresponsiveness to either bradykinin or methacholine, in contrast to a decrease in bronchial reactivity to AMP [40] . These data support the hypothesis that, in contrast to the adenosine-induced airflow limitation, bradykinin-induced airway narrowing does not involve mast cell activation.
In summary, bradykinin is a potent pro-inflammatory peptide which exerts its effects secondary to stimulation of C-fibre endings and the release of TKs. Therefore, this challenge is currently used to examine the role of axon reflexes under various experimental conditions, e.g. following allergen challenge [4] . The development of specific nonpeptide bradykinin receptor antagonists will lead to both an increased understanding of the importance of kinins as asthma mediators and to potentially useful therapies [72] . However, the high cost of these peptides will probably limit their use to research purposes.
Sodium metabisulphite and sulphur dioxide
Sulphur dioxide (SO 2 ) and sulphites are fairly ubiquitous: SO 2 is a common air pollutant, and sulphites including metabisulphite (MBS), bisulphite, and sulphite are commonly used in the processing and storage of foods and drinks. In addition, sulphites are also formed in the atmosphere as a reaction product of SO 2 and water droplets [102, 103] . When dissolved in water, such as in the mucous membrane lining of the airways, these sulphur substances enter into a pH-dependent equilibrium with one another. Sulphur dioxide and metabisulphite convert to bisulphite, and bisulphite in turn enters into equilibrium with sulphite [103] . The airflow limitating effects of sodium sulphite aerosols were clearly pH-dependent, with the greatest effects occurring at the most acid pH tested (pH 4); however, acidity per se does not appear to be the stimulus to airflow limitation. Rather than exerting a direct effect, decreasing pH most likely increases the effects by altering the relative concentrations of sulphite, bisulphite and SO 2 gas. Bisulphite and SO 2 seem to be more potent than sulphite [103] .
The ability of inhaled SO 2 to produce airflow limitation has been recognized for decades. Brief exposure (10 min) to 5 parts per million (ppm) SO 2 or more increases airway resistance in healthy volunteers [104] . Subjects with mild asthma develop airflow limitation at a lower threshold concentration of SO 2 and with greater magnitude than do nonasthmatic subjects [105] . Inhaled sulphite aerosols are a stimulus to airflow limitation in subjects with asthma. This effect of sulphite is not restricted to patients with a clinical history of sulphite sensitivity or to subjects who demonstrate sensitivity to oral ingestion of metabisulphite [103, 106] .
The characteristics of the responses to inhaled MBS are very similar to those seen following inhalation of SO 2 , suggesting that MBS acts by release of SO 2 . The shape of the dose-response curves to SO 2 [107] and MBS [108] are characteristically steep. The time course of responses to MBS and SO 2 are also similar. Onset of the response occurs within the first minute of inhalation and reaches a maximum within 2±5 min. Offset is relatively rapid, the lung function returning to within 10% of baseline within 30 min [105, 108, 109] .
Refractoriness to MBS challenge has been described in several studies [110±112] . Inhibitory prostaglandins, such as PGE 2 may play a role, as treatment with indomethacin induces a small reduction in refractoriness [110] . In addition, cross refractoriness between MBS and exercise challenge has been shown; it was hypothesized that the common component may also involve the generation of inhibitory prostanoids [113] .
Pretreatment with the histamine H 1 receptor antagonist terfenadine had no influence on MBS-induced airflow limitation, which argues against a role for histamine in the mechanism of MBS-induced airflow limitation [114] . Cyclooxygenase products appear to contribute to a limited extent to the airway response to SO 2 [112] and MBS [24], as nonsteroidal anti-inflammatory drugs (NSAIDs) slightly attenuate the induced airflow limitation. The source of prostanoids that contribute to the bronchoconstrictive response to SO 2 (PGD 2 , PGF 2a and TX) remains undetermined. A single oral dose (20 mg) of the leukotriene receptor antagonist zafirlukast attenuated SO 2 -induced bronchoconstriction in patients with asthma, implying that leukotriene release is also involved [115] .
A role for vagal reflex pathways is suggested by the protective actions of anticholinergic drugs in some studies [104, 105, 112, 116] . Other authors, using other methodology and dosing did not confirm these findings [117] or detected protective effects in only some of their tested subjects. A few studies have looked into the possibility of release of sensory neuropeptides (SP and NKA), following MBS inhalation. Inhalation of the NEP inhibitor thiorphan was found to increase airflow limitation to inhaled MBS in normal subjects, suggesting that tachykinins are involved [118] . In contrast, oral administration of the NEP inhibitor acetorphan did not affect inhaled MBS-induced airflow limitation in atopic asthmatics [119] . The contribution of tachykinins has not yet been specifically been investigated in man. In guinea pigs in vivo, it was shown that both antagonists for the NK 1 (CP 96,345) and NK 2 (SR 48968) tachykinin receptors inhibited airflow limitation induced by inhaled MBS [120] . These results are compatible with the hypothesis that MBS stimulates sensory nerves, leading to airflow limitation by noncholinergic as well as cholinergic pathways.
It has been shown that 4 mg of inhaled nedocromil sodium is more effective than 10 mg of inhaled SCG in preventing MBS- [121] and SO 2 -induced airflow limitation [30] in asthmatics or nonasthmatic, atopic subjects. Both drugs are known to stabilize mast cells and to inhibit airway afferent nerve activity. Pretreatment with the nitric oxide (NO) synthase inhibitor L-NMMA did not affect MBS-induced bronchoconstriction and refractoriness suggesting that endogenous NO-production is unlikely to be involved in the airway response to MBS [122] . Inhaled furosemide attenuates MBS-induced airflow limitation in asthmatics; this effect appears to be independent from interaction with the Na/K/Cl cotransporter protein or with carbonic anhydrase [123, 124] . It has been suggested that furosemide acts by promoting production of bronchoprotective prostaglandins such as PGE 2 in the airway [124] ; however, the one report in which this hypothesis was specifically tested in the setting of MBS-induced airflow limitation failed to confirm this [125] . On the other hand, inhalation of 100 mg of PGE 2 did provide considerable protection against MBS-induced airflow limitation, while having only little or no effect on methacholine-induced airflow limitaton [126] .
Inhalation of heparin did not protect against MBS and methacholine challenge in asthma, arguing against an inhibitory effect on neural pathways or airway smooth muscle [127] . Conversely, inhaled magnesium sulphate was shown to mildly attenuate MBS-induced airflow limitation in asthmatics; its mechanism of action is as yet not established. One hypothesis states that Mg ++ would interfere with Ca ++ handling of the bronchial smooth muscle cells [128] .
Pretreatment with 2,000 mg of inhaled beclomethasone dipropionate per day for a mean duration of 26 days, a course enough to significantly reduce airway responsiveness to histamine, methacholine and isocapnic hyperventilation of air, has no consistent effect on SO 2 -induced airflow limitation [129] . Inhaled budesonide (800 mg b.d.) for 14 days reduced airway responsiveness to MBS and methacholine to a similar degree (~1 doubling dose), but this effect was significantly smaller than the reduction of responsiveness to AMP [39] .
In summary, SO 2 is a common air pollutant, which is considered to be a stimulus to investigate the role of cholinergic and/ or noncholinergic neural pathways in airway narrowing. Instead of administering gaseous SO 2 it is much simpler to aerosolize sodium MBS, a SO 2 -generating solution [3] . SO 2 and MBS challenges may be used to distinguish asthma from chronic obstructive pulmonary disease, but this needs further investigation [130] . The lack of sound reproducibility studies for this challenge may hamper interpretation of the data obtained with MBS and SO 2 .
Propranolol (b-blockers)
When given by inhalation, propranolol induces airflow limitation in asthmatic patients but not in normal subjects [131, 132] . Bronchial responsiveness to inhaled propranolol, measured as PD20, is safely measurable in nearly all (>95%) children and adults with asthma and this response is reproducible [133] . Peak propranolol-induced airflow limitation is reached within 2±3 min, persists for~20 min and is followed by a gradual and spontaneous recovery over a period of at least 1 h [131] . It has been shown that the decrease in FEV1 after propranolol challenge did not return within 5% of baseline values after 90 min [134] . The effect of propranolol inhalation on FEV1 even lasts for up to 8 h and counteracts the normal diurnal variation in FEV1 in most asthmatics. This makes propranolol challenge tests less suitable for studying indirect bronchial responsiveness within one day and makes it impossible to determine whether tachyphylaxis occurs following repeated propranolol challenge with a time interval up to 8 h [135] . Measurement of propranolol responsiveness appears to be reproducible from day to day when these tests are repeated within a time interval of one week [136] .
The mechanism of b-blocker-induced airflow limitation in asthmatic patients is still not fully understood. Beta receptor blockade appears to be involved, as the L-isomer of infused propranolol causes airflow limitation, whereas the D-isomer, which is without significant b-receptor blocking activity, does not [137] .
The evidence regarding involvement of mast cells in propranolol-induced airflow limitation is limited and conflicting [137±139]. Pretreatment with the cys LT 1 receptor antagonist pranlukast did not protect against propranololinduced bronchoconstriction, suggesting that cysteinyl leukotrienes are not involved [140] . b-blocker-induced airflow limitation involves cholinergic mechanisms. Indeed, anticholinergic agents are protective against the propranolol challenge; moreover, they reverse the ongoing airflow limitation [131, 141, 142] . In patients with more severe asthma there may be additional mechanisms by which b-blockers cause airflow limitation. A role for sensory nerve hyperresponsiveness has been proposed [143] , based on the results of work on animals.
The effects obtained with inhaled cromones are variable, with positive effects being reported with 20 mg of diSCG [144] , and borderline, nonsignificant protection with a dose of 10 mg of diSCG and nedocromil sodium [145] .
Furosemide (40 mg nebulized) also attenuates propranolol-induced airflow limitation [146] . Inhaled corticosteroids, given as 4 weeks of treatment with daily doses of 1,000 mg of beclomethasone dipropionate [134] or with 400 mg of budesonide [147] , did not reduce the bronchial responsiveness to inhaled propranolol.
In summary, bronchial challenges with propranolol are currently essentially of pathophysiological relevance.
Physical stimuli

Exercise
The occurrence and severity of exercise-induced bronchoconstriction (EIB) depend on the level of ventilation reached and sustained during exercise, the water content and the temperature of the air inspired during exercise, and the interval since exercise last induced an attack of asthma. In the pulmonary function laboratory, EIB can be demonstrated in 70% to 80% of patients with asthma who exercise at 40±60% of their predicted maximum voluntary ventilation for 6±8 min while breathing room air. The maximal airflow limitation is usually recorded within 3±12 min after exercise. The majority of patients recover spontaneously from EIB within 30 min. The severity of EIB cannot be predicted from the resting level of lung function. EIB may occur at any age and is equally common in adults and children [4, 148] .
It is thought that EIB is initiated by the abnormally high rate of water loss from the airways in bringing large volumes of air to alveolar conditions in a relatively short time. Water loss from the respiratory tract results in both cooling of the larger airways and dehydration of the mucosa lining these airways [148] . The mechanisms by which water loss induces airway narrowing in asthma are thought to be a transient hyperosmolarity of the periciliary fluid [149] and/or a transient oedema of the airway wall [150] . It is now acknowledged that airway cooling per se is not essential for EIB to occur; the critical event would be the rate of rewarming the airways during recovery from hyperpnoea. The vascular hypothesis of EIB suggests that the bronchial circulation vasoconstricts in response to airway cooling, and on cessation of hyperpnoea reactive hyperaemia and oedema of the airway wall occur, due to rapid expansion of the blood volume in peribronchial vascular plexi [150] . The osmolarity hypothesis, in contrast, suggests that the abnormally high rate of evaporative water loss from the airways during exercise and hyperventilation causes an increase in ion concentration of the periciliary fluid and that hyperosmolarity of this fluid acts as the stimulus to EIB [149] . The precise pathway by which an increase in osmolarity leads to airflow limitation is not known. It has been shown that bronchoconstrictor mediators are released in response to a hyperosmolar stimulus. Mast cells and epithelial cells are the likely source of these mediators [151] . In addition, neural pathways may also be activated directly by changes in airways osmolarity and temperature and/or by the mediators released in response to these same stimuli, resulting in reflex bronchoconstriction and increased microvascular permeability and oedema [148] .
The refractory period after EIB, has been defined as the time during which less than half of the initial airway response will be provoked by a second challenge. Approximately 50% of patients are refractory to a second exercise challenge performed within 60 min [4, 148] ; when the interval between exercise tests increases to 3 h the initial bronchial response returns in most subjects [152] . Exercise and hypertonic saline challenges were found to induce refractoriness interchangeably, suggesting that they produced a refractory period through a very similar pathway [153] .
Repeated adenosine 5'-monophosphate (AMP) inhalation challenge induces tachyphylaxis to AMP [13] . The finding that repeated AMP bronchoprovocation also attenuates subsequent responsiveness to exercise suggests a shared mechanism of refractoriness [154] . This common mechanism may be related to mast cell mediator release, being induced both by AMP [16] and by hypertonic stimulation [151] .
A contribution of histamine to EIB has been demonstrated using histamine H 1 receptor antagonists, of which terfenadine (60±180 mg) has been most extensively studied [155±158] (table 3) . Prostanoids also appear to play a role in eliciting EIB. Oral pretreatment with 150 mg of the cyclo-oxygenase inhibitor flurbiprofen attenuates EIB [158] . Although oral administration of indomethacin did not alter airflow limitation after exercise [159, 160] , pretreatment with inhaled indomethacin significantly attenuated EIB [161] . Furthermore, the inhalation of 100 mg of PGE 2 [162] or of 250±500 mg of prostacyclin (PGI 2 ) [163] was also effective in inhibiting EIB. Oral pretreatment with the TX prostanoid receptor antagonists GR32191 [164] and BAY u 3405 [165] , however, did not modulate EIB, thus not supporting a role for contractile prostanoids acting through the TP receptor. Since the report, in which the intravenously administered cysLT 1 antagonist MK-571 was shown to markedly attenuate EIB [166] , cysteinyl leukotrienes have been recognized as major mediators in EIB. Subsequent studies, assessing pretreatment with 5-lipoxygenase inhibitors, such as zileuton [167] or ABT-761 (atreleuton) [22, 168] , or with cysLT 1 receptor antagonists, such as zafirlukast (ICI 204,219) [169] , SK&F 104353 [170] , or montelukast (MK-0476) [171, 172] consistently confirmed these findings.
Neural factors are also implicated in the pathogenesis of EIB. The fact that clinically used doses of inhaled ipratropium bromide exert a protective effect, suggests that cholinergic mechanisms also contribute to EIB [173±175]. There is a wide interindividual variation in the response to anticholinergic drugs; their protective effects appear to be more marked in those patients in whom the main site of airflow limitation is in the large central airways [176] . The possible involvement of the excitatory nonadrenergic/noncholinergic (NANC) system in EIB was studied in a clinical trial with administration of a tachykinin receptor antagonist. Inhalation of 2.5 mg of FK-888, a tachykinin NK 1 receptor antagonist, administered as dry powder, did not significantly attenuate the maximal fall in specific airway conductance, but did shorten the recovery phase [177] . SCG and NED have been shown to be effective in up to 80% of patients with EIB [178±180]. Increasing the dose of SCG from 2± 20 mg via MDI increases its protective effect [181] ; such a dose dependency was not found for doses, ranging from 0.5 to 20 mg . mL -1 nebulized nedocromil sodium, suggesting that these doses already lie near the top of the dose response curve [182] . The duration of their protective effect is~2 h [178, 180] .
Nebulized furosemide attenuates EIB in a dose-dependent fashion [183] . The finding that pretreatment with the cox inhibitor indomethacin diminishes the protective effect of nebulized furosemide suggests that the beneficial effects of the latter are due to production of inhibitory prostanoids, such as PGE 2 [184] . Nebulized HMWH LMWH prevents EIB [185, 186] . The mechanism underlying the protective effect of inhaled heparin is not known. In vitro, heparin has been shown to act as a specific blocker of inositol 1,4,5-triphosphate (IP 3 )-binding to its receptors and to inhibit IP 3 -induced Ca++ release.
Finally, several studies demonstrated that continuous treatment with inhaled steroids for periods of at least 3 weeks afford significant partial protection against EIB, in children [187, 188] as well as in adults [189] .
In summary, it is generally accepted that exercise is the bronchial challenge test that most closely resembles the circumstances which an asthmatic patient is likely to encounter in their everyday life. In clinical situations, exercise tests are not very sensitive, but are highly specific for the diagnosis of asthma, and are particularly useful in children, army recruits and athletes. In addition, the challenge is also very interesting from a pathophysiological point of view, and is a useful challenge in the evaluation of various antiasthmatic medications [4, 148] .
Aerosols of hypertonic saline
Hyperosmolar aerosols are potent stimuli for airflow limitation in asthmatics, whereas normal subjects only rarely react [190±194] . The osmolarity of the solution appears to be the most important determinant of the airway response: the more hypertonic the nebulized solution becomes, the bigger the airway response [190] . Although hyperosmolarity by itself is a cause of airflow limitation, it was subsequently shown that excess ion concentration is an additional factor contributing to the response [195] . Furthermore, it is likely that the type of ion used is also an important factor, as it was found that 10% KCl (molarity, 1.34) is more potent than 10% NaCl (molarity, 1.73) [44] .
The methodology of the challenge has been standardized. A concentration of 4.5% saline is most commonly used; 80% of clinically recognized asthmatics have a PD20 of #15 mL [4] . A person who responds to 4.5% saline usually also has exercise-induced asthma. The osmolarity is slightly above sea water, and the test is also used for screening scuba divers. A suitably prepared dry powder of NaCl may potentially be an alternative to "wet" NaCl aerosols [196] . Another hyperosmolar challenge which has been proposed as an alternative for hypertonic NaCl is a bronchial provocation test using a dry powder of mannitol [197, 198] . A dry powder preparation of mannitol can provoke airflow limitation in asthmatic subjects who are sensitive to a wet aerosol of 4.5% NaCl and methacholine, whereas healthy subjects do not react [197] . Asthmatics, responsive to inhalation of dry air during exercise or hyperventilation, are also responsive to inhaled mannitol [198] .
The airway response to hypertonic (HS) is usually maximal 1±3 min and, for most persons, the maximum response occurs 60±90 s after exposure. Spontaneous recovery in FEV1 after the challenge occurs for most asthmatics within 30 min if the fall is <25%. About half of the patients will have a refractory period after HS challenge [153, 199] . A good concordance has been found between between sensitivity to HS and exercise [153, 200±202] . The sensitivity to HS was not significantly related to ultrasonically nebulized distilled water (UNDW) challenge in adults [203] and in a mixed age group [202] , while a good correlation was found in one trial, studying children [204] . These differences may be related to differences in age characteristics as well as to methodological differences, the latter trial [204] using cold UNDW at 48C, while water at room temperature was used in both other trials [202, 203] . A good concordance also exists between HS and isocapnic hyperventilation [192, 202] .
The finding that the refractory period following HS challenge is characterized by an increase in airways responsiveness to AMP would suggest that HS-induced airflow limitation is not associated with mast cell depletion of preformed mediators [14] . However, it has been shown that human lung mast cells release histamine via a non IgE-mediated pathway following a hyperosmolar stimulus in vitro [151] . In vitro studies on isolated central airways from nonasthmatics have confirmed that a hyperosmolar stimulus releases acetylcholine, histamine and neuropeptides [205] . Release of mediators (histamine, PGD 2 , and PGF 2a ) was observed following endobronchial challenge with HS in asthmatics [206] , but this was not confirmed by others [207] . In addition, it has been repeatedly shown that H 1 -antihistamines effectively inhibit HS-induced airflow limitation in asthmatics [208± 211] . Given the lack of effect of indomethacin [212] and the only modest effect of the cox inhibitor flurbiprofen [209] , the contribution of prostanoids appears to be minor.
Clinical studies with anticholinergic drugs have all shown protective effects against HS challenge, but with wide variations between subjects [173, 191, 213] . Similarly, nebulized lidocaine hydrochloride inhibits the airway response to HS in some patients, whilst being ineffective in others [213] . A role for sensory nerves in HS challenge was suggested by the finding that C fibres in dogs were stimulated by injection of hypertonic saline into a lobar bronchus [214] . In other animal models, hypertonic aerosols promote sensory neuropeptide release from C fibres [215] . Intravenous administration of CP-99,994, an NK 1 tachykinin receptor antagonist, did not significantly inhibit HS-induced airflow limitation in subjects with mild asthma [216] ; however it is not known whether the dosing used was able to antagonize airway effects of the sensory neuropeptides SP and NKA.
The HS-induced airflow limitation is attenuated following pretreatment with inhaled SCG [173, 191, 217] . Similar effects have been demonstrated with NED [218, 219] . It is proposed that nedocromil sodium and cromolyn sodium can affect water transport into and out of the epithelial cells by their action on chloride ion channels [219] . Inhaled furosemide is also very protective against HS challenge [220, 221] . These effects were not blocked by pretreatment with indomethacin, suggesting that the protective action of furosemide is not secondary to PGE 2 release [221] .
Finally, three open studies have dealt with the effect of iGCS on the airway response to HS. In one study,~8 weeks of treatment with beclomethasone dipropionate (dose range 600±1,500 mg . day -1 ) attenuated the bronchial responsiveness [222] . In a second study, similar results were obtained following 24±56 days of 1,000 mg of budesonide per day [217] . In a third trial, 1,000 mg budesonide . day -1 during 20 weeks, attenuated the responsiveness for HS more than that for histamine, the difference just failing to reach statistical significance [223] .
The bronchial challenge using HS is mainly of pathophysiological importance. Challenge with HS is easier and cheaper to use because expensive equipment and a source of dry air is not required as with exercise or hyperventilation. The ability to obtain a dose-response curve rather than a single response and the ability to collect inflammatory cells at the same time ("induced sputum") make challenge with HS an attractive technique [224] . Diving with a snorkel or self-contained underwater breathing apparatus (scuba) is a situation in which the patient with asthma may be at risk, as accidental inhalation of seawater is common. HS challenge is therefore useful for assessing persons with a past history of asthma who wish to scuba dive, in order to identify those persons at increased risk [225] .
Aerosols of ultrasonically nebulized distilled water
In 1968, it was reported that the inhalation of an aerosol of distilled water could induce an increase in airflow limitation in patients with asthma [226] . Aerosols of distilled water (fog) have been used for bronchial provocation testing in both adults and children. Although a number of different techniques have been described, a standardized procedure has been proposed. The protocol has many points in common with that for bronchoprovocation with inhalation of hypertonic saline aerosols [4] . Ultrasonic nebulizers are recommended for the generation of hypotonic aerosols; distilled water is most commonly used (UNDW) [227] .
Normal subjects only rarely experience airflow limitation upon inhalation of UNDW, while the majority of asthmatics do [155, 190, 228, 229] . Changing the temperature of the inhaled water from body temperature (368C) to room temperature (228C) results in similar changes in airflow limitation [191] . The more hypotonic the inhaled solution becomes, the stronger the stimulus for inducing airflow limitation [190] . It is not the lack of ions in distilled water that causes airflow limitation, but its lack of osmolarity: distilled water (which lacks both ions and osmolarity) causes airflow limitation, whereas a solution of dextrose in water (which also lacks ions but is iso-osmolar) only rarely induces airflow limitation [195] . When equivalent doses of water were inhaled on two occasions, 40 min apart, a phenomenon of refractoriness was detected [191] . About half of the patients are refractory to the effects of repeated UNDW challenge and this phenomenon can persist for at least 2 h after the initial UNDW challenge [230] . This refractoriness is inhibited by pretreatment with oral indomethacin [231] .
It has consistently been found that airway responsiveness to inhaled methacholine [203, 230, 232±234] and histamine [233] is increased 40±60 min after challenge with UNDW; the clinical relevance of these small increases, however, is uncertain. This increase in sensitivity is not related to the bronchoconstrictor effect of the water [200] and is blocked by prior inhalation of SCG [234] . A good concordance was found between UNDW and exercise challenge [235±237] . A strong correlation between the airway responses to UNDW and cold air hyperventilation was found in one trial [238] , but not in three other studies [239±241] .
Histamine is involved in bronchoconstriction induced by UNDW. Human peripheral blood basophils release histamine upon exposure to water in vitro [242] . H1-antihistamines were reported to attenuate the airflow limitation induced by UNDW [210, 211, 243] . The role of cox products has been studied by several authors. A pretreatment with oral indomethacin did not significantly affect the airway responsiveness to UNDW, but it did prevent the occurrence of a refractory period [231] . Oral aspirin was shown to prevent UNDW-induced airflow limitation in a dose-related manner [244] . The inhaled route appears to provide an even better and longer lasting protection, lysine acetylsalicylate (L-ASA) being more effective than indomethacin [245] . Pretreatment with inhaled PGE 1 and PGE 2 [228] or PGI 2 (prostacyclin) [163] also has protective effects. A contribution of leukotrienes is suggested by the attenuating effect of a single oral dose of the 5-lipoxygenase inhibitor zileuton [246] .
Anticholinergic drugs have been shown to have protective effects against UNDW challenge, but only in a part of the patients [191, 228, 247±251] . In all studies there was a wide variation in the response to these drugs. Interestingly, morphine sulphate inhibits the UNDWinduced airflow limitation in those asthmatics whose responses are inhibited by atropine, and this effect is reversed by the opiate receptor antagonist naloxone. This suggests that opiate receptor stimulation by morphine causes inhibition of the vagally mediated component of water-induced airflow limitation [252] . A role for sensory nerves in UNDW challenge was suggested from experiments in dogs [214] and guinea-pigs [253] .
Several studies have consistently confirmed the protective effects of inhaled SCG [191, 228, 235, 247, 249, 250, 254, 255] . Only a few authors have studied the effects of inhaled nedocromil sodium, obtaining similar results [254, 256, 257] . In contrast with corticosteroids, the protective effect of SCG and NED is immediate. NED does not appear to have a long-lasting effect after 8 weeks of administration, as it did not significantly influence the airway reactivity to UNDW, 24 h after it had been discontinued [258] . Several studies have also confirmed the effectiveness of inhaled furosemide in preventing UNDWinduced airflow limitation [255, 259] .
Finally, the effects of prolonged treatments with inhaled corticosteroids were studied in two clinical trials. Beclomethasone dipropionate, given via pMDI at a dose of 800 mg daily, significantly reduced the airway responsiveness to UNDW after 4 and 8 weeks treatment [258] . In a second trial, 6 weeks treatment with fluticasone propionate 750 mg daily was found to be as effective as beclomethasone dipropionate 1,500 mg daily, both given via pMDI [260] .
In summary, at the present time, challenges with UNDW are essentially of pathophysiological interest.
Isocapnic hyperventilation
Although the original description of hyperventilation (HV)-induced airflow limitation was made in 1946 [261] , renewed interest in this method for inducing airflow limitation occurred because of the recognition that HVinduced cooling and/or drying of the airways is the key mechanism of EIB. The precise manner in which the isocapnic hyperventilation (IHV) challenge is performed influences the magnitude of the induced airflow limitation [262] . The major determinants of its magnitude are: the minute ventilation during HV [263] , the duration of the challenge [264] , and the temperature and the water content of the inspired air [265] . It has been shown that the degree of airflow limitation following IHV is dependent upon the duration of hyperventilation [264] . The time until maximal airflow limitation following cessation of HV varies from 5±15 min, and appears shorter as the duration of the challenge increases [264, 266] .
The IHV challenge is to be considered a laboratory nearequivalent of exercise as a bronchoprovocative stimulus. Several IHV protocols have been described; their principle is based on the subject breathing conditioned air, following a protocol for stepwise increase in minute ventilation [4] . Most asthmatics develop airflow limitation upon breathing frigid dry air at high minute ventilation. This corresponds to the clinical observation that some asthmatics develop airflow limitation by walking in cold weather. In contrast to asthmatics, normal subjects are much less sensitive to cold air hyperventilation [193, 267±270] .
An important percentage of subjects display a refractory period, following IHV challenge [262, 271±273] ; as already mentioned, indomethacin blocks the refractory period to exercise, but not to IHV [160] . A good concordance exists between HS and IHV [192, 202] . Four studies have looked into the correlation between the airway responses to UNDW and cold air hyperventilation [238±241]. A strong correlation was found in only one trial [238] , wheras three other studies were unable to detect a significant correlation [239±241].
In general, there is a correlation between the medications which attenuate EIA and those which attenuate IHV-induced airflow limitation. The H 1 -antihistamine terfenadine attenuated IHV-induced airflow limitation in adults [274, 275] , but not in children [156] . Hyperventilation was found to stimulate the release of PGI 2 and PGE 2 in healthy subjects [276] ; however, cox products do not seem to play an important role, as the COX-inhibitors indomethacin [160] and flurbiprofen [275] failed to modify the responses to IHV. Similarly, the PAF antagonist BN 52063 proved to be ineffective [277] . Cysteinyl leukotrienes, on the other hand, do seem to be relevant mediators. Elevated levels of LTC 4 , D 4 , and E 4 were detected in bronchoalveolar lavage fluid of asthmatics, immediately after performing IHV challenge. Moreover, pretreatment with the 5-lipoxygenase inhibitors A-64077 [278] and zileuton [279] , and with the 5-lipoxygenase activating protein inhibitor BAYx 1005 [280] consistently produced significant blunting of the IHV challenge.
Inhaled anticholinergic drugs partially protect against the challenge, but there are wide variations between subjects [281±283]. The role of sensory C fibres in IHVinduced airflow limitation, using specific tachykinin receptor antagonists, has not yet been specifically studied in man. The participation of both NK 1 and NK 2 receptors in a guinea pig model of IHV, however, has been established [284] .
Both SCG [283, 285±287] and NED [286, 287] have shown to be effective in reducing airway responses to IHV; the duration of the protective effect, however, is short [287] . Furosemide has been shown to be an effective agent against IHV challenge, in both adults [288, 289] and children [290] .
Finally, 4±6 weeks of treatment with inhaled corticosteroids also attenuate the airway hyperresponsiveness to IHV; this has been shown with doses of 1,000±2,000 mg of beclomethasone [129, 291] as well as with 1,600 mg of budesonide [189] , all given via metered-dose inhaler (pMDI).
In summary, IHV challenge reproduces the symptoms produced by exercise. The complex technical requirements, however, limit its widespread application [4] .
Implications for future research
The airway narrowing in asthma is the ultimate result of an interaction between complex and multiple mechanisms not necessarily and uniquely related to airway inflammation [292] . In spite of this fact, BHR in asthma is associated with ongoing airway inflammation and can therefore be considered as a physiological marker of acute as well as chronic inflammation. The results of the different bronchial challenge tests are only weakly correlated and therefore not mutually interchangeable, each test implicitly providing different and perhaps complementary information on the multiple pathways leading to airway narrowing [4] .
Among the indirect challenges the physical stimuli have been widely studied and some of them have been well standardized [4, 5] . For some of the pharmacological indirect stimuli (e.g. MBS, bradykinin, propranolol) there is a need for better standardization. Although measurements of airway responsiveness have a good safety record [4, 224, 293] , severe bronchoconstriction can occur and a case of fatal asthma has been described after nebulization of UNDW [294] .
It has been suggested that indirectly acting bronchial stimuli would better reflect the degree of airway inflammation than directly acting stimuli [41] . Limited data has been published on this subject. A number of studies suggest that adenosine (AMP) might be a potentially useful marker [43] , with a closer relationship to the underlying acute inflammatory process than methacholine to the early asthmatic response following allergen challenge [295] or to allergen avoidance [42] . It has also been shown that sputum eosinophilia is more closely associated with airway responsiveness to bradykinin than to methacholine [296] .
The number of papers, comparing the effect of antiinflammatory medication on an indirect as well as on a direct stimulus in the same patients is currently very small. In all of them, inhaled glucocorticosteroids were used, and this during periods varying from 2±20 weeks, thus assessing the potential early anti-inflammatory benefits of this class of drugs. Again, adenosine appeared to be a better marker than a directly acting stimulus [39, 40] . Other trials, comparing a direct stimulus with bradykinin [40, 101] , exercise [189] or IHV [129, 189] failed to detect significant differences. More work needs to be performed in order to more conclusively confirm the validity of the concept that indirect stimuli are more sensitive markers of airway inflammation, to identify the most suitable bronchial stimulus to be used, and to clarify the issue whether assessing early anti-inflammatory effects of certain drug classes is of clinical relevance to the management of asthmatic patients. An European Respiratory Society Task Force is currently developping recommendations on the use of indirect challenges in the diagnosis and monitoring of asthma, and the results should become available within the next year. 
